Alyeska Investment Group
SUPN icon

Alyeska Investment Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Alyeska Investment Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-148,001
Closed -$1.23M – 575
2014
Q4 		$1.23M Buy
148,001
+48,454
+49% +$407K 0.02% 379
2014
Q3 		$865K Buy
+99,547
New +$899K 0.02% 337
2013
Q4 		– Sell
-100,000
Closed -$733K – 375
2013
Q3 		$733K Buy
+100,000
New +$672K 0.03% 273

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group's SUPN Position: Q1 2015 in Review

Alyeska Investment Group sold out of Supernus Pharmaceuticals (SUPN) in Q1 2015, closing a stake of 148,001 shares — an estimated $1.23M sold.

Alyeska Investment Group first reported a position in SUPN in Q3 2013 and held it in 3 quarters. The position peaked at $1.23M in Q4 2014. 119 funds tracked by Wall St. Rank hold SUPN as of Q1 2015.

  • Alyeska Investment Group reported no remaining Supernus Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Alyeska Investment Group sold 148,001 Supernus Pharmaceuticals shares in Q1 2015, an estimated $1.23M.
  • Alyeska Investment Group first reported a position in Supernus Pharmaceuticals in Q3 2013 and held it in 3 quarters.
  • Alyeska Investment Group's Supernus Pharmaceuticals position peaked at $1.23M in Q4 2014.
  • 119 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2015.

Based on Alyeska Investment Group's 13F filing for Q1 2015, filed 15 May 2015.